Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6412497 | 0.89 | KMT2A (0.43) | S1PR1MEN1KMT2ACA2ALDH1A1 | |
| SCHEMBL6474364 | 0.86 | ALDH1A1 (0.49) | S1PR1MEN1KMT2ACA2ALDH1A1 | |
| SCHEMBL6410180 | 0.85 | CA2 (0.42) | S1PR1MEN1KMT2ACA2ALDH1A1 | |
| SCHEMBL6408893 | 0.83 | L3MBTL1 (0.41) | MEN1KMT2ACA2ALDH1A1POLB | |
| SCHEMBL6412672 | 0.82 | S1PR1 (0.37) | S1PR1MEN1KMT2ACA2ALDH1A1 | |
| SCHEMBL6406805 | 0.82 | KMT2A (0.47) | S1PR1MEN1KMT2ACA2ALDH1A1 | |
| SCHEMBL6408177 | 0.79 | KMT2A (0.38) | MEN1KMT2ACA2ALDH1A1TSHR | |
| SCHEMBL6408847 | 0.78 | FFAR1 (0.35) | — | |
| SCHEMBL6410411 | 0.76 | MAPT (0.44) | MEN1KMT2AALDH1A1TSHRNPSR1 | |
| SCHEMBL6406120 | 0.74 | L3MBTL1 (0.41) | ALDH1A1TSHRNPSR1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288526-A1 | Process for production of 2-(hydroxymethyl)cyclo-propanecarboxylic acids | SUMITOMO CHEMICAL COMPAY LIMTED (JP) | 2005-12-29 | — | — | US | disclosed |
| EP-1538141-A1 | PROCESS FOR PRODUCTION OF 2-(HYDROXYMETHYL)CYCLO- PROPANECARBOXYLIC ACIDS | Sumitomo Chemical Company, Limited (JP) | 2005-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288526-A1 | Process for production of 2-(hydroxymethyl)cyclo-propanecarboxylic acids | GRHPR, PCCA, C5 | S1PR1 1639/4885MEN1 333/4885KMT2A 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.